Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

64.80 +0.33 (+0.51%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,436,152
Open 64.43
Bid (Size) 64.01 (1)
Ask (Size) 64.89 (3)
Prev. Close 64.47
Today's Range 63.90 - 64.84
52wk Range 57.19 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.38%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Portugal's Positive Approach to Teaching Teens about the Birds, Bees and STIs
SOURCE: Gilead Sciences 
Via 3BL Media
Why NRX Pharmaceuticals Shares Are Trading Lower During Premarket On Thursday?
 
Via Benzinga

Performance

YTD
-10.72%
-10.72%
1 Month
+5.21%
+5.21%
3 Month
+6.02%
+6.02%
6 Month
-7.78%
-7.78%
1 Year
-1.67%
-1.67%

More News

Read More
Murder For Hire? What You Need To Know About Enochian Biosciences Co-Founder's Arrest
Via Benzinga
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
Via 3BL Media
Recent Stock Purchase May 2022
Via Talk Markets
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022
Via Benzinga
Gilead at Forefront of Herculean Effort to Combat COVID-19
Via 3BL Media
Gilead Reaches Number One Spot as Top Overall Philanthropic Funder of HIV-Related Programs, According to Funders Concerned About AIDS Report
From Gilead Sciences, Inc.
Via Business Wire
Gilead Stock Earns Rating Upgrade After Quick Turnaround
Via Investor's Business Daily
Living with Metastatic Bladder Cancer: Joey's Journey
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
From Gilead Sciences, Inc.
Via Business Wire
Where Gilead Sciences Stands With Analysts
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Via Benzinga
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
From Gilead Sciences, Inc.
Via Business Wire
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
Via Talk Markets
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
Stocks Are Undervalued
Via Talk Markets
Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV
Via 3BL Media
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Via Investor's Business Daily
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Via Investor's Business Daily
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
Via 3BL Media
Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
Via Benzinga
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.